Lexeo Therapeutics (LXEO) COO sells 3,016 shares to cover RSU taxes

Rhea-AI Filing Summary

Lexeo Therapeutics Chief Operating Officer Jose Manuel Otero reported an open-market sale of 3,016 shares of common stock on February 18, 2026 at a weighted average price of $6.3972 per share. The sale was made to cover tax obligations on the release of restricted stock units. After this transaction, Otero beneficially owned 125,460 shares, including 104,216 restricted stock units.

Insider Trade Summary

Net Seller: 3,016 shares ($19,294)

Net Sell 1 txn

Insider Otero Jose Manuel

Role Chief Operating Officer

Sold 3,016 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,016	$6.3972	$19K

Holdings After Transaction: Common Stock — 125,460 shares (Direct)

Footnotes (1)

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $6.22 to $6.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 104,216 Restricted Stock Units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S(1)		3,016	D	$6.3972(2)	125,460(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $6.22 to $6.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 104,216 Restricted Stock Units.

	/s/ Carole Rosenberg, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lexeo Therapeutics (LXEO) disclose in this Form 4 filing?

Lexeo Therapeutics reported that its COO, Jose Manuel Otero, sold 3,016 shares of common stock on February 18, 2026 at a weighted average price of $6.3972 per share to cover tax obligations on restricted stock units.

How many Lexeo Therapeutics (LXEO) shares did the COO sell and at what price?

Jose Manuel Otero sold 3,016 shares of Lexeo Therapeutics common stock at a weighted average price of $6.3972. The trades were executed in multiple transactions within a price range of $6.22 to $6.47 per share.

Why did the Lexeo Therapeutics (LXEO) COO sell shares in this transaction?

The filing states the sale represents shares sold to cover tax obligations arising from the release of restricted stock units. This indicates the transaction is related to equity compensation taxation rather than a discretionary open-market sale for portfolio rebalancing.

How many Lexeo Therapeutics (LXEO) shares does the COO own after the sale?

After the sale, Jose Manuel Otero beneficially owned 125,460 shares of Lexeo Therapeutics common stock. This total includes 104,216 restricted stock units, reflecting both settled shares and unvested equity awards held following the reported transaction.

What security and transaction type are reported for Lexeo Therapeutics (LXEO)?

The Form 4 reports a transaction in Common Stock classified as a non-derivative security. The transaction code is S, described as a sale in an open market or private transaction, with footnotes clarifying it was used to cover tax obligations.

What price details are provided for the Lexeo Therapeutics (LXEO) insider sale?

The filing notes a weighted average sale price of $6.3972 per share for the 3,016 shares sold. It states trades occurred at prices between $6.22 and $6.47, and full trade breakdowns are available upon request from specified parties.